S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells.
Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing
substances to them without harming normal cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by
monoclonal antibody therapy in treating patients who have newly diagnosed follicular
non-Hodgkin's lymphoma.